311 related articles for article (PubMed ID: 35777588)
21. Review of natural products actions on cytokines in inflammatory bowel disease.
Hur SJ; Kang SH; Jung HS; Kim SC; Jeon HS; Kim IH; Lee JD
Nutr Res; 2012 Nov; 32(11):801-16. PubMed ID: 23176791
[TBL] [Abstract][Full Text] [Related]
22. Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair.
Lei F; Zeng F; Yu X; Deng Y; Zhang Z; Xu M; Ding N; Tian J; Li C
J Nanobiotechnology; 2023 Aug; 21(1):275. PubMed ID: 37596598
[TBL] [Abstract][Full Text] [Related]
23. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
24. [New molecules in the treatment of inflammatory bowel disease].
Chaparro M; Gisbert JP
Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943
[TBL] [Abstract][Full Text] [Related]
25. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease.
Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X
Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374
[TBL] [Abstract][Full Text] [Related]
26. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
27. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic implications of functional tea ingredients for ameliorating inflammatory bowel disease: a focused review.
Huang Y; Xing K; Qiu L; Wu Q; Wei H
Crit Rev Food Sci Nutr; 2022; 62(19):5307-5321. PubMed ID: 33635174
[TBL] [Abstract][Full Text] [Related]
29. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
30. Natural Nuclear Factor Kappa Beta Inhibitors: Safe Therapeutic Options for Inflammatory Bowel Disease.
Tambuwala MM
Inflamm Bowel Dis; 2016 Mar; 22(3):719-23. PubMed ID: 26717321
[TBL] [Abstract][Full Text] [Related]
31. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
32. [Changing paradigm in the management of inflammatory bowel disease].
Jang BI
Korean J Gastroenterol; 2015 May; 65(5):268-72. PubMed ID: 25998972
[TBL] [Abstract][Full Text] [Related]
33. Polyphenols and inflammatory bowel disease: Natural products with therapeutic effects?
Vaghari-Tabari M; Alemi F; Zokaei M; Moein S; Qujeq D; Yousefi B; Farzami P; Hosseininasab SS
Crit Rev Food Sci Nutr; 2024; 64(13):4155-4178. PubMed ID: 36345891
[TBL] [Abstract][Full Text] [Related]
34. Resveratrol attenuates intestinal injury in irradiated rats via PI3K/Akt/mTOR signaling pathway.
Radwan RR; Karam HM
Environ Toxicol; 2020 Feb; 35(2):223-230. PubMed ID: 31633274
[TBL] [Abstract][Full Text] [Related]
35. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
Danese S; Angelucci E
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
[TBL] [Abstract][Full Text] [Related]
36. Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-κB signaling pathways.
Park S; Regmi SC; Park SY; Lee EK; Chang JH; Ku SK; Kim DH; Kim JA
Eur J Pharmacol; 2014 Jul; 735():184-92. PubMed ID: 24769511
[TBL] [Abstract][Full Text] [Related]
37. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.
El Mourabet M; El-Hachem S; Harrison JR; Binion DG
Curr Drug Targets; 2010 Feb; 11(2):234-41. PubMed ID: 19916950
[TBL] [Abstract][Full Text] [Related]
38. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy.
Wang X; Yan J; Wang L; Pan D; Xu Y; Wang F; Sheng J; Li X; Yang M
Theranostics; 2020; 10(23):10808-10822. PubMed ID: 32929381
[No Abstract] [Full Text] [Related]
39. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
[TBL] [Abstract][Full Text] [Related]
40. Rectal delivery of
Fan Y; Wang X; Yan G; Gao H; Yang M
J Mater Chem B; 2023 Dec; 11(47):11228-11234. PubMed ID: 37990919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
